Molecular genetic analysis of haematological malignancies: I. Acute leukaemias and myeloproliferative disorders

Clinical and Laboratory Haematology

Volumn 27, Issue 3, 2005, Pages 148-171

  Bench, Anthony J ^a   Erber, W N ^a   Scott, M A ^a  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

Acute leukaemia; Chronic myeloproliferative disorders; Minimal residual disease; Molecular analysis; Polymerase chain reaction

Indexed keywords

BCR ABL PROTEIN; CD19 ANTIGEN; CD3 ANTIGEN; CD34 ANTIGEN; CHEMOKINE RECEPTOR CXCR4; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; FLT3 LIGAND; HOX PROTEIN; HYBRID PROTEIN; IMATINIB; IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN LIGHT CHAIN; MIXED LINEAGE LEUKEMIA PROTEIN; MOLECULAR MARKER; PROMYELOCYTIC LEUKEMIA PROTEIN; RAS PROTEIN; RETINOIC ACID; RETINOIC ACID RECEPTOR ALPHA; STEM CELL FACTOR; T LYMPHOCYTE RECEPTOR; TRANSCRIPTION FACTOR GATA 1; TRANSCRIPTION FACTOR PU 1; TRANSCRIPTION FACTOR RUNX1; WT1 PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; B LYMPHOCYTE; CHROMOSOME DELETION; CHROMOSOME TRANSLOCATION; CHRONIC MYELOID LEUKEMIA; CLONAL VARIATION; DOWN SYNDROME; EOSINOPHILIC LEUKEMIA; FLUORESCENCE IN SITU HYBRIDIZATION; FUSION GENE; GENE DUPLICATION; GENE MUTATION; GENE REARRANGEMENT; GENOTYPE; HEMATOLOGIC MALIGNANCY; HOX GENE; HUMAN; HUMAN TISSUE; KARYOTYPING; MINIMAL RESIDUAL DISEASE; MOLECULAR GENETICS; MYELOPROLIFERATIVE DISORDER; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; PROMYELOCYTIC LEUKEMIA; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; T LYMPHOCYTE; TRISOMY;

HEMATOLOGIC NEOPLASMS; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE; MOLECULAR DIAGNOSTIC TECHNIQUES; MYELOPROLIFERATIVE DISORDERS; POLYMERASE CHAIN REACTION; TRANSLOCATION, GENETIC; TUMOR MARKERS, BIOLOGICAL;

EID: 20644467034     PISSN: 01419854     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2257.2005.00701.x     Document Type: Review

References (224)

1. Andersson A., Hoglund M., Johansson B., Lassen C., Billstrom R., Garwicz S., Nilsson P.G., Mitelman F. & Fioretos T. (2001) Paired multiplex reverse-transcriptase polymerase chain reaction (PMRT-PCR) analysis as a rapid and accurate diagnostic tool for the detection of MLL fusion genes in hematologic malignancies. Leukemia 15, 1293-1300.
2. Apperley J.F. & Bain B.J. (2004) The FIP1L1-PDGFRA syndrome: a case of mistaken identity? Blood 104, 2999.
3. Arico M., Valsecchi M.G., Camitta B., Schrappe M., Chessells J., Baruchel A., Gaynon P., Silverman L., Janka-Schaub G., Kamps W., Pui C.H. & Masera G. (2000) Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia. New England Journal of Medicine 342, 998-1006.
4. Armstrong S.A., Staunton J.E., Silverman L.B., Pieters R., den Boer M.L., Minden M.D., Sallan S.E., Lander E.S., Golub T.R. & Korsmeyer S.J. (2002) MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Nature Genetics 30, 41-47.
5. Armstrong S.A., Mabon M.E., Silverman L.B., Li A., Gribben J.G., Fox E.A., Sallan S.E. & Korsmeyer S.J. (2004) FLT3 mutations in childhood acute lymphoblastic leukemia. Blood 103, 3544-3546.
6. Asnafi V., Buzyn A., Thomas X., Huguet F., Vey N., Boiron J.M., Reman O., Cayuela J.M., Lheritier V., Vernant J.P., Fiere D., Macintyre E. & Dombret H. (2005) Impact of TCR status and genotype on outcome in adult T acute lymphoblastic leukemia: a LALA-94 study. Blood 105, 3072-3078.
7. Aspland S.E., Bendall H.H. & Murre C. (2001) The role of E2A-PBX1 in leukemogenesis. Oncogene 20, 5708-5717.
8. Avigad S., Kuperstein G., Zilberstein J., Liberzon E., Stark B., Gelernter I., Kodman Y., Luria D., Ash S., Stein J., Goshen Y., Yaniv I., Cohen I.J. & Zaizov R. (1999) TEL-AML1 fusion transcript designates a favorable outcome with an intensified protocol in childhood acute lymphoblastic leukemia. Leukemia 13, 481-483.
9. Ballerini P., Landman Parker J., Laurendeau I., Olivi M., Vidaud M., Adam M., Leverger G., Gerota I., Cayre Y.E. & Bieche I. (2000) Quantitative analysis of TEL/AML1 fusion transcripts by real-time RT-PCR assay in childhood acute lymphoblastic leukemia. Leukemia 14, 1526-1528.
10. Ballerini P., Blaise A., Busson-Le Coniat M., Su X.Y., Zucman-Rossi J., Adam M., van den Akker J., Perot C., Pellegrino B., Landman-Parker J., Douay L., Berger R. & Bernard O.A. (2002) HOX11L2 expression defines a clinical subtype of pediatric T-ALL associated with poor prognosis. Blood 100, 991-997.
11. Barjesteh van Waalwijk van Doorn-Khosrovani S., Erpelinck C., Meijer J., van Oosterhoud S., van Putten W.L., Valk P.J., Beverloo H., Tenen D.G., Lowenberg B. & Delwel R. (2003a) Biallelic mutations in the CEBPA gene and low CEBPA expression levels as prognostic markers in intermediate-risk AML. The Hematology Journal 4, 31-40.
12. Barjesteh van Waalwijk van Doorn-Khosrovani S., Erpelinck C., van Putten W.L., Valk P.J., van der Poel-van de Luytgaarde S., Hack R., Slater R., Smit E.M., Beverloo H.B., Verhoef G., Verdonck L.F., Ossenkoppele G.J., Sonneveld P., de Greef G.E., Lowenberg B. & Delwel R. (2003b) High EVI1 expression predicts poor survival in acute myeloid leukemia: a study of 319 de novo AML patients. Blood 101, 837-845.
13. Barrett J. (2003) Allogeneic stem cell transplantation for chronic myeloid leukemia. Seminars in Hematology 40, 59-71.
14. Baxter E.J., Scott L.M., Campbell P.J., East C., Fourouclas N., Swanton S., Vassiliou G.S., Bench A.J., Boyd E.M., Curtin N., Scott M.A., Erber W.N. & Green A.R. (2005) Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365, 1054-1061.
15. Begley C.G. & Green A.R. (1999) The SCL gene: from case report to critical hematopoietic regulator. Blood 93, 2760-2770.
16. Behm F.G., Smith P.O., Raimondi S.C., Pui C.H. & Bernstein I.D. (1996) Human homologue of the rat chondroitin sulfate proteoglycan, NG2, detected by monoclonal antibody 7.1, identifies childhood acute lymphoblastic leukemias with t(4;11)(q21;q23) or t(11;19)(q23;p13) and MLL gene rearrangements. Blood 87, 1134-1139.
17. Bench A.J., Cross N.C., Huntly B.J., Nacheva E.P. & Green A.R. (2001) Myeloproliferative disorders. Best Practice and Research. Clinical Haematology 14, 531-551.
18. Berger R., Dastugue N., Busson M., Van Den Akker J., Perot C., Ballerini P., Hagemeijer A., Michaux L., Charrin C., Pages M.P., Mugneret F., Andrieux J., Talmant P., Helias C., Mauvieux L., Lafage-Pochitaloff M., Mozziconacci M.J., Cornillet-Lefebvre P., Radford I., Asnafi V., Bilhou-Nabera C., Nguyen Khac F., Leonard C., Speleman F., Poppe B., Bastard C., Taviaux S., Quilichini B., Kerens C., Gregoire M.J., Cave H. & Bernard O.A. (2003) t(5;14)/HOX11L2-positive T-cell acute lymphoblastic leukemia. A collaborative study of the Groupe Français de Cytogenetique Hematologique (GFCH). Leukemia 17, 1851-1857.
19. Bergmann L., Miething C., Maurer U., Brieger J., Karakas T., Weidmann E. & Hoelzer D. (1997) High levels of Wilms' tumor gene (wt1) mRNA in acute myeloid leukemias are associated with a worse long-term outcome. Blood 90, 1217-1225.
20. Biernaux C., Loos M., Sels A., Huez G. & Stryckmans P. (1995) Detection of major bcr-abl gene expression at a very low level in blood cells of some healthy individuals. Blood 86, 3118-3122.
21. Biondi A., Cimino G., Pieters R. & Pui C.H. (2000) Biological and therapeutic aspects of infant leukemia. Blood 96, 24-33.
22. Borkhardt A., Cazzaniga G., Viehmann S., Valsecchi M.G., Ludwig W.D., Burci L., Mangioni S., Schrappe M., Riehm H., Lampert F., Basso G., Masera G., Harbott J. & Biondi A. (1997) Incidence and clinical relevance of TEL/AML1 fusion genes in children with acute lymphoblastic leukemia enrolled in the German and Italian multicenter therapy trials. Associazione Italiana Ematologia Oncologia Pediatrica and the Berlin-Frankfurt-Munster Study Group. Blood 90, 571-577.
23. Bose S., Deininger M., Gora-Tybor J., Goldman J.M. & Melo J.V. (1998) The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: biologic significance and implications for the assessment of minimal residual disease. Blood 92, 3362-3367.
24. Branford S., Hughes T.P. & Rudzki Z. (1999) Monitoring chronic myeloid leukaemia therapy by real-time quantitative PCR in blood is a reliable alternative to bone marrow cytogenetics. British Journal of Haematology 107, 587-599.
25. Branford S., Rudzki Z., Walsh S., Grigg A., Arthur C., Taylor K., Herrmann R., Lynch K.P. & Hughes T.P. (2002) High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood 99, 3472-3475.
26. Branford S., Rudzki Z., Walsh S., Parkinson I., Grigg A., Szer J., Taylor K., Herrmann R., Seymour J.F., Arthur C., Joske D., Lynch K. & Hughes T. (2003) Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood 102, 276-283.
27. Branford S., Rudzki Z., Parkinson I., Grigg A., Taylor K., Seymour J.F., Durrant S., Browett P., Schwarer A.P., Arthur C., Catalano J., Leahy M.F., Filshie R., Bradstock K., Herrmann R., Joske D., Lynch K. & Hughes T. (2004) Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations. Blood 104, 2926-2932.
28. von Bubnoff N., Schneller F., Peschel C. & Duyster J. (2002) BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome- positive leukaemia to STI571: a prospective study. Lancet 359, 487-491.
29. van der Burg M., Poulsen T.S., Hunger S.P., Beverloo H.B., Smit E.M., Vang-Nielsen K., Langerak A.W. & van Dongen J.J. (2004) Split-signal FISH for detection of chromosome aberrations in acute lymphoblastic leukemia. Leukemia 18, 895-908.
30. Byrd J.C., Mrozek K., Dodge R.K., Carroll A.J., Edwards C.G., Arthur D.C., Pettenati M.J., Patil S.R., Rao K.W., Watson M.S., Koduru P.R., Moore J.O., Stone R.M., Mayer R.J., Feldman E.J., Davey F.R., Schiffer C.A., Larson R.A. & Bloomfield C.D. (2002) Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood 100, 4325-4336.
31. Caligiuri M.A., Strout M.P., Schichman S.A., Mrozek K., Arthur D.C., Herzig G.P., Baer M.R., Schiffer C.A., Heinonen K., Knuutila S., Nousiainen T., Ruutu T., Block A.W., Schulman P., Pedersen-Bjergaard J., Croce C.M. & Bloomfield C.D. (1996) Partial tandem duplication of ALL1 as a recurrent molecular defect in acute myeloid leukemia with trisomy 11. Cancer Research 56, 1418-1425.
32. Caligiuri M.A., Strout M.P., Lawrence D., Arthur D.C., Baer M.R., Yu F., Knuutila S., Mrozek K., Oberkircher A.R., Marcucci G., de la Chapelle A., Elonen E., Block A.W., Rao P.N., Herzig G.P., Powell B.L., Ruutu T., Schiffer C.A. & Bloomfield C.D. (1998) Rearrangement of ALL1 (MLL) in acute myeloid leukemia with normal cytogenetics. Cancer Research 58, 55-59.
33. Care R.S., Valk P.J., Goodeve A.C., Abu-Duhier P.M., Geertsma-Kleinekoort W.M., Wilson G.A., Gari M.A., Peake I.R., Lowenberg B. & Reilly J.T. (2003) Incidence and prognosis of c-KIT and FLT3 mutations in core binding factor (CBF) acute myeloid leukaemias. British Journal of Haematology 121, 775-777.
34. Cassinat B., Zassadowski F., Balitrand N., Barbey C., Rain J.D., Fenaux P., Degos L., Vidaud M. & Chomienne C. (2000) Quantitation of minimal residual disease in acute promyelocytic leukemia patients with t(15;17) translocation using real-time RT-PCR. Leukemia 14, 324-328.
35. Cave H., Guidal C., Rohrlich P., Delfau M.H., Broyart A., Lescoeur B., Rahimy C., Fenneteau O., Monplaisir N. & d'Auriol L. (1994) Prospective monitoring and quantitation of residual blasts in childhood acute lymphoblastic leukemia by polymerase chain reaction study of delta and gamma T-cell receptor genes. Blood 83, 1892-1902.
36. Cave H., van der Werff ten Bosch J., Suciu S., Guidal C., Waterkeyn C., Otten J., Bakkus M., Thielemans K., Grandchamp B. & Vilmer E. (1998) Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer - Childhood Leukemia Cooperative Group. New England Journal of Medicine 339, 591-598.
37. Cave H., Suciu S., Preudhomme C., Poppe B., Robert A., Uyttebroeck A., Malet M., Boutard P., Benoit Y., Mauvieux L., Lutz P., Mechinaud F., Grardel N., Mazingue F., Dupont M., Margueritte G., Pages M.P., Bertrand Y., Plouvier E., Brunie G., Bastard C., Plantaz D., Vande Velde I., Hagemeijer A., Speleman F., Lessard M., Otten J., Vilmer E. & Dastugue N. (2004) Clinical significance of HOX11L2 expression linked to t(5;14)(q35;q32), of HOX11 expression, and of SIL-TAL fusion in childhood T-cell malignancies: results of EORTC studies 58881 and 58951. Blood 103, 442-450.
38. Cazzaniga G., Lanciotti M., Rossi V., Di Martino D., Arico M., Valsecchi M.G., Basso G., Masera G., Micalizzi C. & Biondi A. (2002) Prospective molecular monitoring of BCR/ABL transcript in children with Ph+ acute lymphoblastic leukaemia unravels differences in treatment response. British Journal of Haematology 119, 445-453.
39. Chen X., Pan Q., Stow P., Behm F.G., Goorha R., Pui C.H. & Neale G.A. (2001) Quantification of minimal residual disease in T-lineage acute lymphoblastic leukemia with the TAL-1 deletion using a standardized real-time PCR assay. Leukemia 15, 166-170.
40. Cilloni D., Gottardi E., De Micheli D., Serra A., Volpe G., Messa F., Rege-Cambrin G., Guerrasio A., Divona M., Lo Coco F. & Saglio G. (2002) Quantitative assessment of WT1 expression by real time quantitative PCR may be a useful tool for monitoring minimal residual disease in acute leukemia patients. Leukemia 16, 1115-2121.
41. Cimino G., Elia L., Rivolta A., Rapanotti M.C., Rossi V., Alimena G., Annino L., Canaani E., Lo Coco F. & Biondi A. (1996) Clinical relevance of residual disease monitoring by polymerase chain reaction in patients with ALL-1/AF-4 positive-acute lymphoblastic leukaemia. British Journal of Haematology 92, 659-664.
42. Cimino G., Elia L., Rapanotti M.C., Sprovieri T., Mancini M., Cuneo A., Mecucci C., Fioritoni G., Carotenuto M., Morra E., Liso V., Annino L., Saglio G., De Rossi G., Foa R. & Mandelli F. (2000) A prospective study of residual-disease monitoring of the ALL1/AF4 transcript in patients with t(4;11) acute lymphoblastic leukemia. Blood 95, 96-101.
43. Cools J., DeAngelo D.J., Gotlib J., Stover E.H., Legare R.D., Cortes J., Kutok J., Clark J., Galinsky I., Griffin J.D., Cross N.C., Tefferi A., Malone J., Alam R., Schrier S.L., Schmid J., Rose M., Vandenberghe P., Verhoef G., Boogaerts M., Wlodarska I., Kantarjian H., Marynen P., Coutre S.E., Stone R. & Gilliland D.G. (2003) A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. New England Journal of Medicine 348, 1201-1214.
44. Corsetti M.T., Lerma E., Dejana A., Basta P., Ferrara R., Benvenuto F., Vassallo F., Abate M., Piaggio G., Parodi C., Sessarego M., Li Pira G., Manca F. & Carella A.M. (1999) Quantitative competitive reverse transcriptase- polymerase chain reaction for BCR-ABL on Philadelphia-negative leukaphereses allows the selection of low-contaminated peripheral blood progenitor cells for autografting in chronic myelogenous leukemia. Leukemia 13, 999-1008.
45. Corsetti M.T., Lerma E., Dejana A., Cavaliere M., Figari O., Vassallo F., Abate M., Luchetti S., Piaggio G., Parodi C., Li Pira G., Manca F. & Carella A.M. (2000) Cytogenetic response to autografting in chronic myelogenous leukemia correlates with the amount of BCR-ABL positive cells in the graft. Experimental Hematology 28, 104-111.
46. Crist W.M., Carroll A.J., Shuster J.J., Behm F.G., Whitehead M., Vietti T.J., Look A.T., Mahoney D., Ragab A. & Pullen D.J. (1990) Poor prognosis of children with pre-B acute lymphoblastic leukemia is associated with the t(1;19)(q23;p13): a Pediatric Oncology Group Study. Blood 76, 117-122.
47. Cross N.C., Feng L., Chase A., Bungey J., Hughes T.P. & Goldman J.M. (1993) Competitive polymerase chain reaction to estimate the number of BCR-ABL transcripts in chronic myeloid leukemia patients after bone marrow transplantation. Blood 82, 1929-1936.
48. Deininger M.W., Goldman J.M. & Melo J.V. (2000) The molecular biology of chronic myeloid leukemia. Blood 96, 3343-3356.
49. Deininger M., Buchdunger E. & Druker B.J. (2005) The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 105, 2640-2653.
50. Dimartino J.F. & Cleary M.L. (1999) MLL rearrangements in haematological malignancies: lessons from clinical and biological studies. British Journal of Haematology 106, 614-626.
51. Dohner K., Tobis K., Ulrich R., Frohling S., Benner A., Schlenk R.F. & Dohner H. (2002) Prognostic significance of partial tandem duplications of the MLL gene in adult patients 16 to 60 years old with acute myeloid leukemia and normal cytogenetics: a study of the Acute Myeloid Leukemia Study Group Ulm. Journal of Clinical Oncology 20, 3254-3261.
52. van Dongen J.J., Seriu T., Panzer-Grumayer E.R., Biondi A., Pongers-Willemse M.J., Corral L., Stolz F., Schrappe M., Masera G., Kamps W.A., Gadner H., van Wering E.R., Ludwig W.D., Basso G., de Bruijn M.A., Cazzaniga G., Hettinger K., van der Does-van den Berg A., Hop W.C., Riehm H. & Bartram C.R. (1998) Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet 352, 1731-1738.
53. van Dongen J.J., Macintyre E.A., Gabert J.A., Delabesse E., Rossi V., Saglio G., Gottardi E., Rambaldi A., Dotti G., Griesinger F., Parreira A., Gameiro P., Diaz M.G., Malec M., Langerak A.W., San Miguel J.F. & Biondi A. (1999) Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia. Leukemia 13, 1901-1928.
54. van Dongen J.J., Langerak A.W., Bruggemann M., Evans P.A., Hummel M., Lavender F.L., Delabesse E., Davi F., Schuuring E., Garcia-Sanz R., van Krieken J.H., Droese J., Gonzalez D., Bastard C., White H.E., Spaargaren M., Gonzalez M., Parreira A., Smith J.L., Morgan G.J., Kneba M. & Macintyre E.A. (2003) Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia 17, 2257-2317.
55. Donovan J.W., Ladetto M., Zou G., Neuberg D., Poor C., Bowers D. & Gribben J.G. (2000) Immunoglobulin heavy-chain consensus probes for real-time PCR quantification of residual disease in acute lymphoblastic leukemia. Blood 95, 2651-2658.
56. Dreyling M.H., Schrader K., Fonatsch C., Schlegelberger B., Haase D., Schoch C., Ludwig W., Loffler H., Buchner T., Wormann B., Hiddemann W. & Bohlander S.K. (1998) MLL and CALM are fused to AF10 in morphologically distinct subsets of acute leukemia with translocation t(10;11): both rearrangements are associated with a poor prognosis. Blood 91, 4662-4667.
57. Drunat S., Olivi M., Brunie G., Grandchamp B., Vilmer E., Bieche I. & Cave H. (2001) Quantification of TEL-AML1 transcript for minimal residual disease assessment in childhood acute lymphoblastic leukaemia. British Journal of Haematology 114, 281-289.
58. Eckert C., Biondi A., Seeger K., Cazzaniga G., Hartmann R., Beyermann B., Pogodda M., Proba J. & Henze G. (2001) Prognostic value of minimal residual disease in relapsed childhood acute lymphoblastic leukaemia. Lancet 358, 1239-1241.
59. Elia L., Gottardi E., Floriddia G., Grillo R., Ciambelli F., Luciani M., Chiusolo P., Invernizzi R., Meloni G., Foa R., Saglio G. & Cimino G. (2004) Retrospective comparison of qualitative and quantitative reverse transcriptase polymerase chain reaction in diagnosing and monitoring the ALL1-AF4 fusion transcript in patients with acute lymphoblastic leukaemia. Leukemia 18, 1824-1830.
60. Ernst P., Wang J. & Korsmeyer S.J. (2002) The role of MLL in hematopoiesis and leukemia. Current Opinion in Hematology 9, 282-287.
61. Falini B., Flenghi L., Fagioli M., Lo Coco F., Cordone I., Diverio D., Pasqualucci L., Biondi A., Riganelli D., Orleth A., Liso A., Martelli M.F., Pelicci P.G. & Pileri S. (1997) Immunocytochemical diagnosis of acute promyelocytic leukemia (M3) with the monoclonal antibody PG-M3 (anti-PML). Blood 90, 4046-4053.
62. Falini B., Meucci C., Tiacci E., Alcalay M., Rosati R., Pasqualucci L., La Starza R., Diverio D., Colombo E., Santucci A., Bigerna B., Pacini R., Pucciarini A., Liso A., Vignetti M., Fazi P., Meani N., Pettirossi V., Saglio G., Mandelli F., Lo-Coco F., Pelicci P.G. & Martelli M.F. (2005) Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. New England Journal of Medicine 352, 254-266.
63. Ferrando A.A. & Look A.T. (2003) Gene expression profiling in T-cell acute lymphoblastic leukemia. Seminars in Hematology 40, 274-280.
64. Ferrando A.A., Neuberg D.S., Staunton J., Loh M.L., Huard C., Raimondi S.C., Behm F.G., Pui C.H., Downing J.R., Gilliland D.G., Lander E.S., Golub T.R. & Look A.T. (2002) Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. Cancer Cell 1, 75-87.
65. Ferrando A.A., Armstrong S.A., Neuberg D.S., Sallan S.E., Silverman L.B., Korsmeyer S.J. & Look A.T. (2003) Gene expression signatures in MLL-rearranged T-lineage and B-precursor acute leukemias: dominance of HOX dysregulation. Blood 102, 262-268.
66. Ferrando A.A., Neuberg D.S., Dodge R.K., Paietta E., Larson R.A., Wiernik P.H., Rowe J.M., Caligiuri M.A., Bloomfield C.D. & Look A.T. (2004) Prognostic importance of TLX1 (HOX11) oncogene expression in adults with T-cell acute lymphoblastic leukaemia. Lancet 363, 535-536.
67. Ferrara F. & Del Vecchio L. (2002) Acute myeloid leukemia with t(8;21)/AML1/ETO: a distinct biological and clinical entity. Haematologica 87, 306-319.
68. Fleischman E.W., Baturina J.A., Sokova O.I., Popa A.V., Kosorukova I.S. & Rowley J.D. (2003) Prognostic significance of the AML1-ETO fusion transcript expression in children and young adults with t(8;21) acute myeloid leukemia. Haematologica 88, 1078-1079.
69. Foa R., Vitale A., Mancini M., Cuneo A., Mecucci C., Elia L., Lombardo R., Saglio G., Torelli G., Annino L., Specchia G., Damasio E., Recchia A., Di Raimondo F., Morra E., Volpe E., Tafuri A., Fazi P., Hunger S.P. & Mandelli F. (2003) E2A-PBX1 fusion in adult acute lymphoblastic leukaemia: biological and clinical features. British Journal of Haematology 120, 484-487.
70. Friedman A.D. (1999) Leukemogenesis by CBF oncoproteins. Leukemia 13, 1932-1942.
71. Frohling S., Schlenk R.F., Breitruck J., Benner A., Kreitmeier S., Tobis K., Dohner H. & Dohner K. (2002) Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm. Blood 100, 4372-4380.
72. de la Fuente J., Merx K., Steer E.J., Muller M., Szydlo R.M., Maywald O., Berger U., Hehlmann R., Goldman J.M., Cross N.C., Melo J.V. & Hochhaus A. (2001) ABL-BCR expression does not correlate with deletions on the derivative chromosome 9 or survival in chronic myeloid leukemia. Blood 98, 2879-2880.
73. Gabert J., Vey N., Bilhou-Nabera C., Hayette S., Macintyre E., Bastard C., Cayuela J.M., Vaerman J.L., Preudhomme C., Dupont M., Dastugue N., Frenoy N., Raynaud S., Davi F., Gaub M.P., Lafage M., Sutton L., Charrin C., Vernant J.P. & Fiere D. (2001) Improved outcome of adult patients with E2A PBX1/t(1;19) positive ALL after intensive therapy: results of the LALA-94 multicenter protocol. Blood (ASH 2001, Abstract 3493).
74. Gabert J., Beillard E., van der Velden V.H., Bi W., Grimwade D., Pallisgaard N., Barbany G., Cazzaniga G., Cayuela J.M., Cave H., Pane F., Aerts J.L., De Micheli D., Thirion X., Pradel V., Gonzalez M., Viehmann S., Malec M., Saglio G. & van Dongen J.J. (2003) Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program. Leukemia 17, 2318-2357.
75. Garg M., Moore H., Tobal K. & Yin J.A. (2003) Prognostic significance of quantitative analysis of WT1 gene transcripts by competitive reverse transcription polymerase chain reaction in acute leukaemia. British Journal of Haematology 123, 49-59.
76. Gilliland D.G. (2003) FLT3-activating mutations in acute promyelocytic leukaemia: a rationale for risk-adapted therapy with FLT3 inhibitors. Best Practice and Research. Clinical Haematology 16, 409-417.
77. Gotlib J., Cools J., Malone J.M., Schrier S.L., Gilliland D.G. & Coutre S.E. (2004) The FIP1L1-PDGFRα fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management. Blood 103, 2879-2891.
78. Griesshammer M., Klippel S., Strunck E., Temerinac S., Mohr U., Heimpel H. & Pahl H.L. (2004) PRV-1 mRNA expression discriminates two types of essential thrombocythemia. Annals of Hematology 83, 364-370.
79. Grimwade D. (2001) The clinical significance of cytogenetic abnormalities in acute myeloid leukaemia. Best Practice and Research. Clinical Haematology 14, 497-529.
80. Grimwade D. (2002) The significance of minimal residual disease in patients with t(15;17). Best Practice and Research. Clinical Haematology 15, 137-158.
81. Grimwade D., Walker H., Oliver F., Wheatley K., Harrison C., Harrison G., Rees J., Hann I., Stevens R., Burnett A. & Goldstone A. (1998) The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 92, 2322-2333.
82. Group Francais de Cytogenetique Hematologique (1996) Cytogenetic abnormalities in adult acute lymphoblastic leukemia: correlations with hematologic findings outcome. A Collaborative Study of the Group Francais de Cytogenetique Hematologique. Blood 87, 3135-3142.
83. Guerrasio A., Pilatrino C., De Micheli D., Cilloni D., Serra A., Gottardi E., Parziale A., Marmont F., Diverio D., Divona M., Lo Coco F. & Saglio G. (2002) Assessment of minimal residual disease (MRD) in CBFbeta/MYH11-positive acute myeloid leukemias by qualitative and quantitative RT-PCR amplification of fusion transcripts. Leukemia 16, 1176-1181.
84. de Haas V., Breunis W.B., Dee R., Verhagen O.J., Kroes W., van Wering E.R., van Dongen J.J., van den Berg H. & van der Schoot C.E. (2002) The TEL-AML1 real-time quantitative polymerase chain reaction (PCR) might replace the antigen receptor-based genomic PCR in clinical minimal residual disease studies in children with acute lymphoblastic leukaemia. British Journal of Haematology 116, 87-93.
85. Hann I., Vora A., Harrison G., Harrison C., Eden O., Hill F., Gibson B. & Richards S. (2001) Determinants of outcome after intensified therapy of childhood lymphoblastic leukaemia: results from Medical Research Council United Kingdom acute lymphoblastic leukaemia XI protocol. British Journal of Haematology 113, 103-114.
86. Harrison C.J. (2001) Acute lymphoblastic leukaemia. Best Practice and Research. Clinical Haematology 14, 593-607.
87. Higuchi M., O'Brien D., Kumaravelu P., Lenny N., Yeoh E.J. & Downing J.R. (2002) Expression of a conditional AML1-ETO oncogene bypasses embryonic lethality and establishes a marine model of human t(8;21) acute myeloid leukemia. Cancer Cell 1, 63-74.
88. Hochhaus A. (2002) Minimal residual disease in chronic myeloid leukaemia patients. Best Practice and Research. Clinical Haematology 15, 159-178.
89. Hochhaus A., Lin F., Reiter A., Skladny H., Mason P.J., van Rhee F., Shepherd P.C., Allan N.C., Hehlmann R., Goldman J.M. & Cross N.C. (1996) Quantification of residual disease in chronic myelogenous leukemia patients on interferon-alpha therapy by competitive polymerase chain reaction. Blood 87, 1549-1555.
90. Hochhaus A., Reiter A., Saussele S., Reichert A., Emig M., Kaeda J., Schultheis B., Berger U., Shepherd P.C., Allan N.C., Hehlmann R., Goldman J.M. & Cross N.C. (2000) Molecular heterogeneity in complete cytogenetic responders after interferon-α therapy for chronic myelogenous leukemia: low levels of minimal residual disease are associated with continuing remission. German CML Study Group and the UK MRC CML Study Group. Blood 95, 62-66.
91. Hosler G.A., Bash R.O., Bai X., Jain V. & Scheuermann R.H. (1999) Development and validation of a quantitative polymerase chain reaction assay to evaluate minimal residual disease for T-cell acute lymphoblastic leukemia and follicular lymphoma. American Journal of Pathology 154, 1023-1035.
92. Hughes T.P., Kaeda J., Branford S., Rudzki Z., Hochhaus A., Hensley M.L., Gathmann I., Bolton A.E., van Hoomissen I.C., Goldman J.M. & Radich J.P. (2003) Frequency of major molecular responses to imatinib or Interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. New England Journal of Medicine 349, 1423-1432.
93. Hunger S.P. (1996) Chromosomal translocations involving the E2A gene in acute lymphoblastic leukemia: clinical features and molecular pathogenesis. Blood 87, 1211-1224.
94. Hunger S.P., Fall M.Z., Camitta B.M., Carroll A.J., Link M.P., Lauer S.J., Mahoney D.H., Pullen D.J., Shuster J.J., Steuber C.P. & Cleary M.L. (1998) E2A-PBX1 chimeric transcript status at end of consolidation is not predictive of treatment outcome iin childhood acute lymphoblastic leukemias with a t(1;19)(q23;p13): a Pediatric Oncology Group Study. Blood 91, 1021-1028.
95. Huntly B.J., Reid A.G., Bench A.J., Campbell L.J., Telford N., Shepherd P., Szer J., Prince H.M., Turner P., Grace C., Nacheva E.P. & Green A.R. (2001) Deletions of the derivative chromosome 9 occur at the time of the Philadelphia translocation and provide a powerful and independent prognostic indicator in chronic myeloid leukemia. Blood 98, 1732-1738.
96. Huntly B.J., Bench A.J., Delabesse E., Reid A.C., Li J., Scott M.A., Campbell L., Byrne J., Pinto E., Brizard A., Niedermeiser D., Nacheva E.P., Guilhot F., Deininger M. & Green A.R. (2002) Derivative chromosome 9 deletions in chronic myeloid leukemia: poor prognosis is not associated with loss of ABL-BCR expression, elevated BCR-ABL levels, or karyotypic instability. Blood 99, 4547-4553.
97. Huntly B.J., Bench A. & Green A.R. (2003a) Double jeopardy from a single translocation: deletions of the derivative chromosome 9 in chronic myeloid leukemia. Blood 102, 1160-1168.
98. Huntly B.J., Guilhot F., Reid A.G., Vassiliou G., Hennig E., Franke C., Byrne J., Brizard A., Niederwieser D., Freeman-Edward J., Cuthbert G., Bown N., Clark R.E., Nacheva E.P., Green A.R. & Deininger M.W. (2003b) Imatinib improves but may not fully reverse the poor prognosis of patients with CML with derivative chromosome 9 deletions. Blood 102, 2205-2212.
99. Inokuchi K., Yamaguchi H., Hanawa H., Tanosaki S., Nakamura K., Tarusawa M., Miyake K., Shimada T. & Dan K. (2002) Loss of DCC gene expression is of prognostic importance in acute myelogenous leukemia. Clinical Cancer Research 8, 1882-1888.
100. Inoue K., Sugiyama H., Ogawa H., Nakagawa M., Yamagami T., Miwa H., Kita K., Hiraoka A., Masaoka T. & Nasu K. (1994) WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. Blood 84, 3071-3079.
101. Irving J.A., O'Brien S., Lennard A.L., Minto L., Lin F. & Hall A.G. (2004) Use of denaturing HPLC for detection of mutations in the BCR-ABL kinase domain in patients resistant to imatinib. Clinical Chemistry 50, 1233-1237.
102. Jaffe E.S., Harris N.L., Stein H. & Vardiman J.W. (eds) (2001) Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. IARC Press, Lyon, France.
103. Jamal R., Taketani T., Taki T., Bessho F., Hongo T., Hamaguchi H., Horiike S., Taniwaki M., Hanada R., Nakamura H. & Hayashi Y. (2001) Coduplication of the MLL and FLT3 genes in patients with acute myeloid leukemia. Genes, Chromosomes and Cancer 31, 187-190.
104. James C., Ugo V., Le Couedic J.P., Staerk J., Delhommeau F., Lacout C., Garcon L., Raslova H., Berger R., Bennaceur-Griscelli A., Villeval J.L., Constantinescu S.N., Casadevall N. & Vainchenker W. (2005) A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434, 1144-1148.
105. Johansson P., Ricksten A., Wennstrom L., Palmqvist L., Kutti J. & Andreasson B. (2003) Increased risk for vascular complications in PRV-1 positive patients with essential thrombocythaemia. British Journal of Haematology 123, 513-516.
106. Karakas T., Miething C.C., Maurer U., Weidmann E., Ackermann H., Hoelzer D. & Bergmann L. (2002) The coexpression of the apoptosis-related genes bcl-2 and wt1 in predicting survival in adult acute myeloid leukemia. Leukemia 16, 846-854.
107. Kees U.R., Heerema N.A., Kumar R., Watt P.M., Baker D.L., La M.K., Uckun P.M. & Sather H.N. (2003) Expression of HOX11 in childhood T-lineage acute lymphoblastic leukaemia can occur in the absence of cytogenetic aberration at 10q24: a study from the Children's Cancer Group (CCG). Leukemia 17, 887-893.
108. Kelly L.M. & Gilliland D.G. (2002) Genetics of myeloid leukemias. Annual Review of Genomics and Human Genetics 3, 179-198.
109. Klippel S., Strunck E., Temerinac S., Bench A.J., Meinhardt G., Mohr U., Leichtle R., Green A.R., Griesshammer M., Heimpel H. & Pahl H.L. (2003) Quantification of PRV-1 mRNA distinguishes polycythemia vera from secondary erythrocytosis. Blood 102, 3569-3574.
110. Kondo M., Kudo K., Kimura H., Inaba J., Kato K., Kojima S., Matsuyama T. & Horibe K. (2000) Real-time quantitative reverse transcription-polymerase chain reaction for the detection of AML1-MTG8 fusion transcripts in t(8;21)-positive acute myelogenous leukemia. Leukemia Research 24, 951-956.
111. Kottaridis P.D., Gale R.E., Frew M.E., Harrison G., Langabeer S.E., Belton A.A., Walker H., Wheatley K., Bowen D.T., Burnett A.K., Goldstone A.H. & Linch D.C. (2001) The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood 98, 1752-1759.
112. Kottaridis P.D., Gale R.E., Langabeer S.E., Frew M.E., Bowen D.T. & Linch D.C. (2002) Studies of FLT3 mutations in paired presentation and relapse samples from patients with acute myeloid leukemia: implications for the role of FLT3 mutations in leukemogenesis, minimal residual disease detection, and possible therapy with FLT3 inhibitors. Blood 100, 2393-2398.
113. Kottaridis P.D., Gale R.E. & Linch D.C. (2003) Flt3 mutations and leukaemia. British Journal of Haematology 122, 523-538.
114. Kralovics R., Buser A.S., Teo S.S., Coers J., Tichelli A., van der Maas A.P. & Skoda R.C. (2003) Comparison of molecular markers in a cohort of patients with chronic myeloproliferative disorders. Blood 102, 1869-1871.
115. Krauter J., Wattjes M.P., Nagel S., Heidenreich O., Krug U., Kafert S., Bunjes D., Bergmann L., Ganser A. & Heil G. (1999) Real-time RT-PCR for the detection and quantification of AML1/MTG8 fusion transcripts in t(8;21)-positive AML patients. British Journal of Haematology 107, 80-85.
116. Krauter J., Gorlich K., Ottmann O., Lubbert M., Dohner H., Heit W., Kanz L., Ganser A. & Heil G. (2003) Prognostic value of minimal residual disease quantification by real-time reverse transcriptase polymerase chain reaction in patients with core binding factor leukemias. Journal of Clinical Oncology 21, 4413-4422.
117. Kreuzer K.A., Saborowski A., Lupberger J., Appell C., Na I.K., le Coutre P. & Schmidt C.A. (2001) Fluorescent 5′-exonuclease assay for the absolute quantification of Wilms' tumour gene (WT1) mRNA: implications for monitoring human leukaemias. British Journal of Haematology 114, 313-318.
118. Leroy H., Roumier C., Huyghe P., Biggio V., Fenaux P. & Preudhomme C. (2005) CEBPA point mutations in hematological malignancies. Leukemia 19, 329-334.
119. Li A., Zhou J., Zuckerman D., Rue M., Dalton V., Lyons C., Silverman L.B., Sallan S.E. & Gribben J.G. (2003) Sequence analysis of clonal immunoglobulin and T-cell receptor gene rearrangements in children with acute lymphoblastic leukemia at diagnosis and at relapse: implications for pathogenesis and for the clinical utility of PCR-based methods of minimal residual disease detection. Blood 102, 4520-4526.
120. Liang D.C., Shih L.Y., Hung I.J., Yang C.P., Chen S.H., Jaing T.H., Liu H.C. & Chang W.H. (2002) Clinical relevance of internal tandem duplication of the FLT3 gene in childhood acute myeloid leukemia. Cancer 94, 3292-3298.
121. Lin F., Goldman J.M. & Cross N.C. (1994) A comparison of the sensitivity of blood and bone marrow for the detection of minimal residual disease in chronic myeloid leukaemia. British Journal of Haematology 86, 683-685.
122. Liu P.P., Hajra A., Wijmenga C. & Collins F.S. (1995) Molecular pathogenesis of the chromosome 16 inversion in the M4Eo subtype of acute myeloid leukemia. Blood 85, 2289-2302.
123. Madzo J., Zuna J., Muzikova K., Kalinova M., Krejci O., Hrusak O., Otova B., Stary J. & Trka J. (2003) Slower molecular response to treatment predicts poor outcome in patients with TEL/AML1 positive acute lymphoblastic leukemia: prospective real-time quantitative reverse transcriptase-polymerase chain reaction study. Cancer 97, 105-113.
124. Maloney K., McGavran I., Murphy J., Odom L., Stork L., Wei Q. & Hunger S. (1999) TEL-AML1 fusion identifies a subset of children with standard risk acute lymphoblastic leukemia who have an excellent prognosis when treated with therapy that includes a single delayed intensification. Leukemia 13, 1708-1712.
125. Marcucci G., Strout M.P., Bloomfield C.D. & Caligiuri M.A. (1998) Detection of unique ALL1 (MLL) fusion transcripts in normal human bone marrow and blood: distinct origin of normal versus leukemic ALL1 fusion transcripts. Cancer Research 58, 790-793.
126. Marcucci G., Caligiuri M.A., Dohner H., Archer K.J., Schlenk R.F., Dohner K., Maghraby E.A. & Bloomfield C.D. (2001) Quantification of CBFβ/MYH11 fusion transcript by real time RT-PCR in patients with INV(16) acute myeloid leukemia. Leukemia 15, 1072-1080.
127. Maroc N., Morel A., Beillard E., De La Chapelle A.L., Fund X., Mozziconacci M.J., Dupont M., Cayuela J.M., Gabert J., Koki A., Fert V. & Hermitte F. (2004) A diagnostic biochip for the comprehensive analysis of MLL translocations in acute leukemia. Leukemia 18, 1522-1530.
128. Martineau M., Berger R., Lillington D.M., Moorman A.V. & Seeker-Walker L.M. (1998) The t(6;11)(q27;q23) translocation in acute leukemia: a laboratory and clinical study of 30 cases. EU Concerted Action Hq23 Workshop participants. Leukemia 12, 788-791.
129. Matsuno N., Osato M., Yamashita N., Yanagida M., Nanri T., Fukushima T., Motoji T., Kusumoto S., Towatari M., Suzuki R., Naoe T., Nishii K., Shigesada K., Ohno R., Mitsuya H., Ito Y. & Asou N. (2003) Dual mutations in the AML1 and FLT3 genes are associated with leukemogenesis in acute myeloblastic leukemia of the MO subtype. Leukemia 17, 2492-2499.
130. Melo J.V. (1996) The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype. Blood 88, 2375-2384.
131. Melo J.V., Hochhaus A., Yan X.H. & Goldman J.M. (1996) Lack of correlation between ABL-BCR expression and response to interferon-α in chronic myeloid leukaemia. British Journal of Haematology 92, 684-686.
132. Meshinchi S., Woods W.G., Stirewalt D.L., Sweetser D.A., Buckley J.D., Tjoa T.K., Bernstein I.D. & Radich J.P. (2001) Prevalence and prognostic significance of Flt3 internal tandem duplication in pediatric acute myeloid leukemia. Blood 97, 89-94.
133. Mistry A.R., Pedersen E.W., Solomon E. & Grimwade D. (2003) The molecular pathogenesis of acute promyelocytic leukaemia: implications for the clinical management of the disease. Blood Reviews 17, 71-97.
134. Mitterbauer G., Nemeth P., Wacha S., Cross N.C., Schwarzinger I., Jaeger U., Geissler K., Greinix H.T., Kalhs P., Lechner K. & Mannhalter C. (1999a) Quantification of minimal residual disease in patients with BCR-ABL-positive acute lymphoblastic leukaemia using quantitative competitive polymerase chain reaction. British Journal of Haematology 106, 634-643.
135. Mitterbauer G., Zimmer C., Fonatsch C., Haas O., Thalhammer-Scherrer R., Schwarzinger I., Kalhs P., Jaeger U., Lechner K. & Mannhalter C. (1999b) Monitoring of minimal residual leukemia in patients with MLL-AF9 positive acute myeloid leukemia by RT-PCR. Leukemia 13, 1519-1524.
136. Mitterbauer G., Zimmer C., Pirc-Danoewinata H., Haas O.A., Hojas S., Schwarzinger I., Greinix H., Jager U., Lechner K. & Mannhalter C. (2000) Monitoring of minimal residual disease in patients with MLL-AF6-positive acute myeloid leukaemia by reverse transcriptase polymerase chain reaction. British Journal of Haematology 109, 622-628.
137. Miyamoto T., Weissman I.L. & Akashi K. (2000) AML1/ETO-expressing nonleukemic stem cells in acute myelogenous leukemia with 8;21 chromosomal translocation. Proceedings of the National Academy of Sciences of the United States of America 97, 7521-7526.
138. Moreno I., Martin G., Bolufer P., Barragan E., Rueda E., Roman J., Fernandez P., Leon P., Mena A., Cervera J., Torres A. & Sanz M.A. (2003) Incidence and prognostic value of FLT3 internal tandem duplication and D835 mutations in acute myeloid leukemia. Haematologica 88, 19-24.
139. Mrozek K., Heinonen K., Lawrence D., Carroll A.J., Koduru P.R., Rao K.W., Strout M.P., Hutchison R.E., Moore J.O., Mayer R.J., Schiffer C.A. & Bloomfield C.D. (1997) Adult patients with de novo acute myeloid leukemia and t(9;11)(p22;q23) have a superior outcome to patients with other translocations involving band Hq23: a cancer and leukemia group B study. Blood 90, 4532-4538.
140. Mueller B.U., Pabst T., Osato M., Asou N., Johansen L.M., Minden M.D., Behre G., Hiddemann W., Ito Y. & Tenen D.G. (2002) Heterozygous PU.1 mutations are associated with acute myeloid leukemia. Blood 100, 998-1007.
141. Muller-Tidow C., Metzelder S.K., Buerger H., Packeisen J., Ganser A., Heil G., Kugler K., Adiguzel G., Schwable J., Steffen B., Ludwig W.D., Heinecke A., Buchner T., Berdel W.E. & Serve H. (2004) Expression of the p14ARF tumor suppressor predicts survival in acute myeloid leukemia. Leukemia 18, 720-726.
142. Murphy K.M., Levis M., Hafez M.J., Geiger T., Cooper L.C., Smith B.D., Small D. & Berg K.D. (2003) Detection of FLT3 internal tandem duplication and D835 mutations by a multiplex polymerase chain reaction and capillary electrophoresis assay. The Journal of molecular diagnostics 5, 96-102.
143. Nowell P.C. (2002) Progress with chronic myelogenous leukemia: a personal perspective over four decades. Annual Review of Medicine 53, 1-13.
144. Nowell P.C. & Hungerford D.A. (1960) Chromosome studies on normal and leukemic human leukocytes. Journal of the National Cancer Institute 25, 85-109.
145. Nyvold C., Madsen H.O., Ryder L.P., Seyfarth J., Svejgaard A., Clausen N., Wesenberg F., Jonsson O.G., Forestier E. & Schmiegelow K. (2002) Precise quantification of minimal residual disease at day 29 allows identification of children with acute lymphoblastic leukemia and an excellent outcome. Blood 99, 1253-1258.
146. Olavarria E., Kanfer E., Szydlo R., Kaeda J., Rezvani K., Cwynarski K., Pocock C., Dazzi F., Craddock C., Apperley J.F., Cross N.C. & Goldman J.M. (2001) Early detection of BCR-ABL transcripts by quantitative reverse transcriptase-polymerase chain reaction predicts outcome after allogeneic stem cell transplantation for chronic myeloid leukemia. Blood 97, 1560-1565.
147. Ostergaard M., Olesen L.H., Hasle H., Kjeldsen E. & Hokland P. (2004a) WT1 gene expression: an excellent tool for monitoring minimal residual disease in 70% of acute myeloid leukaemia patients - results from a single-centre study. British Journal of Haematology 125, 590-600.
148. Ostergaard M., Stentoft J. & Hokland P. (2004b) A real-time quantitative RT-PCR assay for monitoring DEK-CAN fusion transcripts arising from translocation t(6;9) in acute myeloid leukemia. Leukemia Research 28, 1213-1215.
149. Oyarzo M.P., Lin P., Classman A., Bueso-Ramos C.E., Luthra R. & Medeiros L.J. (2004) Acute myeloid leukemia with t(6;9)(p23;q34) is associated with dysplasia and a high frequency of flt3 gene mutations. American Journal of Clinical Pathology 122, 348-358.
150. Ozeki K., Kiyoi H., Hirose Y., Iwai M., Ninomiya M., Kodera Y., Miyawaki S., Kuriyama K., Shimazaki C., Akiyama H., Nishimura M., Motoji T., Shinagawa K., Takeshita A., Ueda R., Ohno R., Emi N. & Naoe T. (2004) Biologic and clinical significance of the FLT3 transcript level in acute myeloid leukemia. Blood 103, 1901-1908.
151. Pabst T., Mueller B.U., Zhang P., Radomska H.S., Narravula S., Schnittger S., Behre G., Hiddemann W. & Tenen D.G. (2001) Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-α (C/EBPα), in acute myeloid leukemia. Nature Genetics 27, 263-270.
152. Panagopoulos I., Isaksson M., Lindvall C., Bjorkholm M., Ahlgren T., Fioretos T., Heim S., Mitelman F. & Johansson B. (2000) RT-PCR analysis of the MOZ-CBP and CBP-MOZ chimeric transcripts in acute myeloid leukemias with t(8;16)(p11;p13). Genes, Chromosomes and Cancer 28, 415-424.
153. Pane F., Frigeri F., Sindona M., Luciano L., Ferrara F., Cimino R., Meloni G., Saglio G., Salvatore F. & Rotoli B. (1996) Neutrophilic-chronic myeloid leukemia: a distinct disease with a specific molecular marker (BCR/ABL with C3/A2 junction). Blood 88, 2410-2414.
154. Pardanani A., Brockman S.R., Paternoster S.F., Flynn H.C., Ketterling R.P., Lasho T.L., Ho C.L., Li C.Y., Dewald G.W. & Tefferi A. (2004) FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia. Blood 104, 3038-3045.
155. Paschka P., Muller M.C., Merx K., Kreil S., Schoch C., Lahaye T., Weisser A., Petzold A., Konig H., Berger U., Gschaidmeier H., Hehlmann R. & Hochhaus A. (2003) Molecular monitoring of response to imatinib (Glivec) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission. Leukemia 17, 1687-1694.
156. Perego R.A., Costantini M., Cornacchini G., Gargantini L., Bianchi C., Pungolino E., Rovida E. & Morra E. (2000) The possible influences of B2A2 and B3A2 BCR/ABL protein structure on thrombopoiesis in chronic myeloid leukaemia. European Journal of Cancer 36, 1395-1401.
157. Pongers-Willemse M.J., Verhagen O.J., Tibbe G.J., Wijkhuijs A.J., de Haas V., Roovers E., van der Schoot C.E. & van Dongen J.J. (1998) Real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia using junctional region specific TaqMan probes. Leukemia 12, 2006-2014.
158. Pongers-Willemse M.J., Seriu T., Stolz F., d'Aniello E., Gameiro P., Pisa P., Gonzalez M., Bartram C.R., Panzer-Grumayer E.R., Biondi A., San Miguel J.F. & van Dongen J.J. (1999) Primers and protocols for standardized detection of minimal residual disease in acute lymphoblastic leukemia using immunoglobulin and T cell receptor gene rearrangements and TALI deletions as PCR targets: report of the Biomed-1 Concerted Action: investigation of minimal residual disease in acute leukemia. Leukemia 13, 110-118.
159. Preudhomme C., Revillion F., Merlat A., Hornez L., Roumier C., Duflos-Grardel N., Jouet J.P., Cosson A., Peyrat J.P. & Fenaux P. (1999) Detection of BCR-ABL transcripts in chronic myeloid leukemia (CML) using a 'real time' quantitative RT-PCR assay. Leukemia 13, 957-964.
160. Preudhomme C., Sagot C., Boissel N., Cayuela J.M., Tigaud I., de Botton S., Thomas X., Raffoux E., Lamandin C., Castaigne S., Fenaux P. & Dombret H. (2002) Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association (ALFA). Blood 100, 2717-2723.
161. Pui C.H., Gaynon P.S., Boyett J.M., Chessells J.M., Baruchel A., Kamps W., Silverman L.B., Biondi A., Harms D.O., Vilmer E., Schrappe M. & Camitta B. (2002) Outcome of treatment in childhood acute lymphoblastic leukaemia with rearrangement of the 11q23 chromosomal region. Lancet 359, 1909-1915.
162. Pui C.H., Relling M.V. & Downing J.R. (2004) Acute lymphoblastic leukemia. New England Journal of Medicine 350, 1535-1548.
163. Quintas-Cardama A., Kantarjian H., Talpaz M., O'Brien S., Garcia-Manero G., Verstovsek S., Rios M.B., Hayes K., Glassman A., Bekele B.N., Zhou X. & Cortes J. (2005) Imatinib mesylate therapy may overcome the poor prognostic significance of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia. Blood 105, 2281-2286.
164. Radich J.P. (2002) Molecular measurement of minimal residual disease in Philadelphia-positive acute lymphoblastic leukaemia. Best Practice and Research. Clinical Haematology 15, 91-103.
165. Raimondi S.C., Chang M.N., Ravindranath Y., Behm F.G., Gresik M.V., Steuber C.P., Weinstein H.J. & Carroll A.J. (1999) Chromosomal abnormalities in 478 children with acute myeloid leukemia: clinical characteristics and treatment outcome in a cooperative pediatric oncology group study - POG 8821. Blood 94, 3707-3716.
166. Ramakers-van Woerden N.L., Pieters R., Loonen A.H., Hubeek I., van Drunen E., Beverloo H.B., Slater R.M., Harbott J., Seyfarth J., van Wering E.R., Hahlen K., Schmiegelow K., Janka-Schaub G.E. & Veerman A.J. (2000) TEL/AML1 gene fusion is related to in vitro drug sensitivity for L-asparaginase in childhood acute lymphoblastic leukemia. Blood 96, 1094-1099.
167. van der Reijden B.A., Simons A., Luiten E., van der Poel S.C., Hogenbirk P.E., Tonnissen E., Valk P.J., Lowenberg B., De Greef G.E., Breuning M.H. & Jansen J.H. (2002) Minimal residual disease quantification in patients with acute myeloid leukaemia and inv(16)/CBFB-MYH11 gene fusion. British Journal of Haematology 118, 411-418.
168. van Rhee F., Marks D.I., Lin F., Szydlo R.M., Hochhaus A., Treleaven J., Delord C., Cross N.C. & Goldman J.M. (1995) Quantification of residual disease in Philadelphia-positive acute lymphoblastic leukemia: comparison of blood and bone marrow. Leukemia 9, 329-335.
169. Rombouts E.J., Pavic B., Lowenberg B. & Ploemacher R.E. (2004) Relation between CXCR-4 expression, Flt3 mutations, and unfavorable prognosis of adult acute myeloid leukemia. Blood 104, 550-557.
170. Roumier C., Eclache V., Imbert M., Davi F., MacIntyre E., Garand R., Talmant P., Lepelley P., Lai J.L., Casasnovas O., Maynadie M., Mugneret F., Bilhou-Naberra C., Valensi F., Radford I., Mozziconacci M.J., Arnoulet C., Duchayne E., Dastugue N., Cornillet P., Daliphard S., Garnache F., Boudjerra N., Jouault H., Fenneteau O., Pedron B., Berger R., Flandrin G., Penaux P. & Preudhomme C. (2003a) MO AML, clinical and biologic features of the disease, including AML1 gene mutations: a report of 59 cases by the Groupe Francais d'Hematologie Cellulaire (GFHC) and the Groupe Francais de Cytogenetique Hematologique (GFCH). Blood 101, 1277-1283.
171. Roumier C., Fenaux P., Lafage M., Imbert M., Eclache V. & Preudhomme C. (2003b) New mechanisms of AML1 gene alteration in hematological malignancies. Leukemia 17, 9-16.
172. Rowe D., Cotterill S.J., Ross P.M., Bunyan D.J., Vickers S.J., Bryon J., McMullan D.J., Griffiths M.J., Reilly J.T., Vandenberghe E.A., Wilson G., Watmore A.E. & Bown N.P. (2000) Cytogenetically cryptic AML1-ETO and CBFβ-MYH11 gene rearrangements: incidence in 412 cases of acute myeloid leukaemia. British Journal of Haematology 111, 1051-1056.
173. Rubnitz J.E., Behm F.G., Curcio-Brint A.M., Pinheiro R.P., Carroll A.J., Raimondi S.C., Shurtleff S.A. & Downing J.R. (1996) Molecular analysis of t(11;19) breakpoints in childhood acute leukemias. Blood 87, 4804-4808.
174. Rubnitz J.E., Downing J.R., Pui C.H., Shurtleff S.A., Raimondi S.C., Evans W.E., Head D.R., Crist W.M., Rivera G.K., Hancock M.L., Boyett J.M., Buijs A., Grosveld G. & Behm F.G. (1997) TEL gene rearrangement in acute lymphoblastic leukemia: a new genetic marker with prognostic significance. Journal of Clinical Oncology 15, 1150-1157.
175. Rubnitz J.E., Raimondi S.C., Tong X., Srivastava O.K., Razzouk B.I., Shurtleff S.A., Downing J.R., Pui C.H., Ribeiro R.C. & Behm F.G. (2002) Favorable impact of the t(9;11) in childhood acute myeloid leukemia. Journal of Clinical Oncology 20, 2302-2309.
176. Satake N., Sakashita A., Kobayashi H., Maseki N., Sakurai M. & Kaneko Y. (1997) Minimal residual disease in acute monocytic leukemia patient with trisomy 11 and partial tandem duplication of MLL. Cancer Genetics and Cytogenetics 96, 26-29.
177. Scheuring U.J., Pfeifer H., Wassmann B., Bruck P., Gehrke B., Petershofen E.K., Gschaidmeier H., Hoelzer D. & Ottmann O.G. (2003a) Serial minimal residual disease (MRD) analysis as a predictor of response duration in Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL) during imatinib treatment. Leukemia 17, 1700-1706.
178. Scheuring U.J., Pfeifer H., Wassmann B., Bruck P., Atta J., Petershofen E.K., Gehrke B., Gschaidmeier H., Hoelzer D. & Ottmann O.G. (2003b) Early minimal residual disease (MRD) analysis during treatment of Philadelphia chromosome/Bcr-Abl-positive acute lymphoblastic leukaemia with Abl-tyrosine kinase inhibitor imatinib (STI571). Blood 101, 85-90.
179. Schmidt H.H., Strehl S., Thaler D., Strunk D., Sill H., Linkesch W., Jager U., Sperr W., Greinix H.T., Konig M., Emberger W. & Haas O.A. (2004) RT-PCR and FISH analysis of acute myeloid leukemia with t(8;16)(p11;p13) and chimeric MOZ and CBP transcripts: breakpoint cluster region and clinical implications. Leukemia 18, 1115-1121.
180. Schnittger S., Kinkelin U., Schoch C., Heinecke A., Haase D., Haferlach T., Buchner T., Wormann B., Hiddemann W. & Griesinger F. (2000) Screening for MLL tandem duplication in 387 unselected patients with AML identify a prognostically unfavorable subset of AML. Leukemia 14, 796-804.
181. Schnittger S., Schoch C., Dugas M., Kern W., Staib P., Wuchter C., Loffler H., Sauerland C.M., Serve H., Buchner T., Haferlach T. & Hiddemann W. (2002) Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood 100, 59-66.
182. Schnittger S., Weisser M., Schoch C., Hiddemann W., Haferlach T. & Kern W. (2003) New score predicting for prognosis in PML-RARA+, AML1-ETO+, or CBFB-MYH11+ acute myeloid leukemia based on quantification of fusion transcripts. Blood 102, 2746-2755.
183. Schnittger S., Schoch C., Kern W., Hiddemann W. & Haferlach T. (2004) FLT3 length mutations as marker for follow-up studies in acute myeloid leukaemia. Acta Haematologica 112, 68-78.
184. Schoch C., Kohlmann A., Schnittger S., Brors B., Dugas M., Mergenthaler S., Kern W., Hiddemann W., Eils R. & Haferlach T. (2002) Acute myeloid leukemias with reciprocal rearrangements can be distinguished by specific gene expression profiles. Proceedings of the National Academy of Sciences of the United States of America 99, 10008-10013.
185. Schoch C., Schnittger S., Klaus M., Kern W., Hiddemann W. & Haferlach T. (2003) AML with 11q23/MLL abnormalities as defined by the WHO classification: incidence, partner chromosomes, FAB subtype, age distribution, and prognostic impact in an unselected series of 1897 cytogenetically analyzed AML cases. Blood 102, 2395-2402.
186. Scholl C., Breitinger H., Schlenk R.F., Dohner H., Frohling S. & Dohner K. (2003) Development of a real-time RT-PCR assay for the quantification of the most frequent MLL/AF9 fusion types resulting from translocation t(9;11)(p22;q23) in acute myeloid leukemia. Genes, Chromosomes and Cancer 38, 274-280.
187. Seeker-Walker L.M., Prentice H.G., Durrant J., Richards S., Hall E. & Harrison G. (1997) Cytogenetics adds independent prognostic information in adults with acute lymphoblastic leukaemia on MRC trial UKALL XA. MRC Adult Leukaemia Working Party. British Journal of Haematology 96, 601-610.
188. Seeger K., Kreuzer K.A., Lass U., Taube T., Buchwald D., Eckert C., Korner G., Schmidt C.A. & Henze G. (2001) Molecular quantification of response to therapy and remission status in TEL-AML1-positive childhood ALL by real-time reverse transcription polymerase chain reaction. Cancer Research 61, 2517-2522.
189. Shah N.P., Nicoll J.M., Nagar B., Gorre M.E., Paquette R.L., Kuriyan J. & Sawyers C.L. (2002) Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2, 117-125.
190. Sheikhha M.H., Awan A., Tobal K. & Yin J.A. (2003) Prognostic significance of FLT3 ITD and D835 mutations in AML patients. The Hematology Journal 4, 41-46.
191. Shepherd P., Suffolk R., Halsey J. & Allan N. (1995) Analysis of molecular breakpoint and m-RNA transcripts in a prospective randomized trial of interferon in chronic myeloid leukaemia: no correlation with clinical features, cytogenetic response, duration of chronic phase, or survival. British Journal of Haematology 89, 546-554.
192. Shiah H.S., Kuo Y.Y., Tang J.L., Huang S.Y., Yao M., Tsay W., Chen Y.C., Wang C.H., Shen M.C., Lin D.T., Lin K.H. & Tien H.F. (2002) Clinical and biological implications of partial tandem duplication of the MLL gene in acute myeloid leukemia without chromosomal abnormalities at Hq23. Leukemia 16, 196-202.
193. Shih L.Y., Huang C.F., Wu J.H., Lin T.L., Dunn P., Wang P.N., Kuo M.C., Lai C.L. & Hsu H.C. (2002) Internal tandem duplication of FLT3 in relapsed acute myeloid leukemia: a comparative analysis of bone marrow samples from 108 adult patients at diagnosis and relapse. Blood 100, 2387-2392.
194. Shih L.Y., Kuo M.C., Liang D.C., Huang CF., Lin T.L., Wu J.H., Wang P.N., Dunn P. & Lai C.L. (2003) Internal tandem duplication and Asp835 mutations of the FMS-like tyrosine kinase 3 (FLT3) gene in acute promyelocytic leukemia. Cancer 98, 1206-1216.
195. Slovak M.L., Kopecky K.J., Cassileth P.A., Harrington D.H., Theil K.S., Mohamed A., Paietta E., Willman C.L., Head D.R., Rowe J.M., Forman S.J. & Appelbaum F.R. (2000) Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood 96, 4075-4083.
196. Soekarman D., Vonlindern M., Daenen S., Dejong B., Fonatsch C., Heinze B., Bartram C., Hagemeijer A. & Grosveld G. (1992) The translocation (6;9)(p23;q34) shows consistent rearrangement of 2 genes and defines a myeloproliferative disorder with specific clinical features. Blood 79, 2990-2997.
197. Steinbach D., Hermann J., Viehmann S., Zintl F. & Gruhn B. (2002) Clinical implications of FRAME gene expression in childhood acute myeloid leukemia. Cancer Genetics and Cytogenetics 133, 118-123.
198. Steudel C., Wermke M., Schaich M., Schakel U., Illmer T., Ehninger G. & Thiede C. (2003) Comparative analysis of MLL partial tandem duplication and FLT3 internal tandem duplication mutations in 956 adult patients with acute myeloid leukemia. Genes, Chromosomes and Cancer 37, 237-251.
199. Stirewalt D.L. & Radich J.P. (2003) The role of FLT3 in haematopoietic malignancies. Natural Reviews. Cancer 3, 650-665.
200. Stirewalt D.L., Kopecky K.J., Meshinchi S., Appelbaum F.R., Slovak M.L., Willman C.L. & Radich J.P. (2001) FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia. Blood 97, 3589-3595.
201. Szczepanski T., Flohr T., van der Velden V.H., Bartram C.R. & van Dongen J.J. (2002a) Molecular monitoring of residual disease using antigen receptor genes in childhood acute lymphoblastic leukaemia. Best Practice and Research. Clinical Haematology 15, 37-57.
202. Szczepanski T., Willemse M.J., Brinkhof B., van Wering E.R., van der Burg M. & van Dongen J.J. (2002b) Comparative analysis of Ig and TCR gene rearrangements at diagnosis and at relapse of childhood precursor-B-ALL provides improved strategies for selection of stable PCR targets for monitoring of minimal residual disease. Blood 99, 2315-2323.
203. Takahashi Y., Horibe K., Kiyoi H., Miyashita Y., Fukuda M., Mori H., Nozaki C., Hasegawa S., Kawabe T., Kato K., Kojima S., Matuyama T. & Naoe T. (1998) Prognostic significance of TEL/AML1 fusion transcript in childhood B-precursor acute lymphoblastic leukemia. Journal of Pediatric Hematology/Oncology 20, 190-195.
204. Taketani T., Taki T., Sugita K., Furuichi Y., Ishii E., Hanada R., Tsuchida M., Ida K. & Hayashi Y. (2004) FLT3 mutations in the activation loop of tyrosine kinase domain are frequently found in infant ALL with MLL rearrangements and pediatric ALL with hyperdiploidy. Blood 103, 1085-1088.
205. Temerinac S., Klippel S., Strunck E., Roder S., Lubbert M., Lange W., Azemar M., Meinhardt G., Schaefer H.E. & Pahl H.L. (2000) Cloning of PRV-1, a novel member of the uPAR receptor superfamily, which is overexpressed in polycythemia rubra vera. Blood 95, 2569-2576.
206. Tenen D.G. (2003) Disruption of differentiation in human cancer: AML shows the way. Natural Reviews. Cancer 3, 89-101.
207. Thiede C., Steudel C., Mohr B., Schaich M., Schakel U., Platzbecker U., Wermke M., Bornhauser M., Ritter M., Neubauer A., Ehninger G. & Illmer T. (2002) Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood 99, 4326-4335.
208. Tobal K. & Yin J.A. (1996) Monitoring of minimal residual disease by quantitative reverse transcriptase-polymerase chain reaction for AML1-MTG8 transcripts in AML-M2 with t(8; 21). Blood 88, 3704-3709.
209. Tobal K., Newton J., Macheta M., Chang J., Morgenstern G., Evans P.A., Morgan G., Lucas O.S. & Yin J.A. (2000) Molecular quantitation of minimal residual disease in acute myeloid leukemia with t(8;21) can identify patients in durable remission and predict clinical relapse. Blood 95, 815-819.
210. Trka J., Kalinova M., Hrusak O., Zuna J., Krejci O., Madzo J., Sedlacek P., Vavra V., Michalova K., Jarosova M. & Stary J. (2002) Real-time quantitative PCR detection of WT1 gene expression in children with AML: prognostic significance, correlation with disease status and residual disease detection by flow cytometry. Leukemia 16, 1381-1389.
211. Tse W., Meshinchi S., Alonzo T.A., Stirewalt D.L., Gerbing R.B., Woods W.G., Appelbaum F.R. & Radich J.P. (2004) Elevated expression of the AF1q gene, an MLL fusion partner, is an independent adverse prognostic factor in pediatric acute myeloid leukemia. Blood 104, 3058-3063.
212. Uckun P.M., Sensel M.G., Sun L., Steinherz P.G., Trigg M.E., Heerema N.A., Sather H.N., Reaman G.H. & Gaynon P.S. (1998) Biology and treatment of childhood T-lineage acute lymphoblastic leukemia. Blood 91, 735-746.
213. Uckun P.M., Pallisgaard N., Hokland P., Navara C., Narla R., Gaynon P.S., Sather H. & Heerema N. (2001) Expression of TEL-AML1 fusion transcripts and response to induction therapy in standard risk acute lymphoblastic leukemia. Leukemia and Lymphoma 42, 41-56.
214. Valk P.J., Verhaak R.G., Beijen M.A., Erpelinck C.A., Barjesteh van Waalwijk van Doorn-Khosrovani S., Boer J.M., Beverloo H.B., Moorhouse M.J., van der Spek P.J., Lowenberg B. & Delwel R. (2004) Prognostically useful gene-expression profiles in acute myeloid leukemia. New England Journal of Medicine 350, 1617-1628.
215. Verstovsek S., Lin H., Kantarjian H., Saglio G., De Micheli D., Pane F., Garcia-Manero G., Intrieri M., Rotoli B., Salvatore F., Quo J.Q., Talpaz M., Specchia G., Pizzolo G., Liberati A.M., Cortes J., Quackenbush R.C. & Arlinghaus R.B. (2002) Neutrophilic-chronic myeloid leukemia: low levels of p230 BCR/ABL mRNA and undetectable BCR/ABL protein may predict an indolent course. Cancer 94, 2416-2425.
216. Wang L., Pearson K., Ferguson J.E. & Clark R.E. (2003) The early molecular response to imatinib predicts cytogenetic and clinical outcome in chronic myeloid leukaemia. British Journal of Haematology 120, 990-999.
217. Wattjes M.P., Krauter J., Nagel S., Heidenreich O., Ganser A. & Heil G. (2000) Comparison of nested competitive RT-PCR and real-time RT-PCR for the detection and quantification of AML1/MTG8 fusion transcripts in t(8;21) positive acute myelogenous leukemia. Leukemia 14, 329-335.
218. Wechsler J., Greene M., McDevitt M.A., Anastasi J., Karp J.E., Le Beau M.M. & Crispino J.D. (2002) Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome. Nature Genetics 32, 148-152.
219. Weisberg E., Manley P.W., Breitenstein W., Bruggen J., Cowan-Jacob S.W., Ray A., Huntly B., Fabbro D., Fendrich G., Hall-Meyers E., Kung A.L., Mestan J., Daley G.Q., Callahan L., Catley L., Cavazza C., Mohammed A., Neuberg D., Wright R.D., Gilliland D.G. & Griffin J.D. (2005) Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 7, 129-141.
220. Yamamoto Y., Kiyoi H., Nakano Y., Suzuki R., Kodera Y., Miyawaki S., Asou N., Kuriyama K., Yagasaki F., Shimazaki C., Akiyama H., Saito K., Nishimura M., Motoji T., Shinagawa K., Takeshita A., Saito H., Ueda R., Ohno R. & Naoe T. (2001) Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood 97, 2434-2439.
221. Yeoh E.J., Ross M.E., Shurtleff S.A., Williams W.K., Patel D., Mahfouz R., Behm F.G., Raimondi S.C., Relling M.V., Patel A., Cheng C., Campana D., Wilkins D., Zhou X., Li J., Liu H., Pui C.H., Evans W.E., Naeve C., Wong L. & Downing J.R. (2002) Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell 1, 133-143.
222. Yin J.A. (2002) Minimal residual disease in acute myeloid leukaemia. Best Practice and Research. Clinical Haematology 15, 119-135.
223. Yokota, H., Tsuno N.B., Tanaka Y., Fukui T., Kitamura K., Hirai H., Osumi K., Itou N., Satoh H., Okabe M. & Nakahara K. (2002) Quantification of minimal residual disease in patients with e1a2 BCR-ABL-positive lymphoblastic leukemia using a real-time RT-PCR assay. Leukemia 16, 1167-1175.
224. Zwaan C.M., Meshinchi S., Radich J.P., Veerman A.J., Huismans D.R., Munske L., Podleschhy M., Hahlen K., Pieters R., Zimmermann M., Reinhardt D., Harbott J., Creutzig U., Kaspers G.J. & Griesinger F. (2003) FLT3 Internal tandem duplication in 234 children with acute myeloid leukemia: prognostic significance and relation to cellular drug resistance. Blood 102, 2387-2394.